RedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® Apr 18, 2017
DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants Apr 14, 2017
DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting Apr 6, 2017
RedHill Biopharma Receives FDA Orphan Drug Designation for YELIVA® for the Treatment of Cholangiocarcinoma Apr 5, 2017
RedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam® Apr 5, 2017
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017 Mar 29, 2017
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities Mar 19, 2017
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office Mar 15, 2017
DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD Mar 3, 2017
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial Feb 24, 2017
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease Feb 14, 2017
DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) Feb 14, 2017
DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) Jan 26, 2017
RedHill Biopharma Announces QIDP Fast-Track Designation Granted by FDA to RHB-104 for Nontuberculous Mycobacteria Infections Jan 12, 2017
